_PHARMACEUITICALS_PRIVATE_LIMITED.webp)
Richfield (India) Pharmaceuiticals Profile
Key Indicators
- Authorised Capital ₹ 0.95 M
as on 17-11-2024
- Paid Up Capital ₹ 0.91 M
as on 17-11-2024
- Company Age 19 Year, 25 Days
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 1.00 Cr
as on 17-11-2024
- Revenue -12.75%
(FY 2023)
- Profit -15.94%
(FY 2023)
- Ebitda -13.93%
(FY 2023)
- Net Worth 33.61%
(FY 2023)
- Total Assets 8.22%
(FY 2023)
About Richfield (India) Pharmaceuiticals
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.95 M and a paid-up capital of Rs 0.91 M.
The company currently has active open charges totaling ₹1.00 Cr.
Suman Jain, Laxmilal Jain, Nisha Jain, and One other member serve as directors at the Company.
- CIN/LLPIN
U85110KA2005PTC037914
- Company No.
037914
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
12 Dec 2005
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Bangalore
Industry
Company Details
- Location
Dharwad, Karnataka, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Richfield (India) Pharmaceuiticals?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Laxmilal Jain  | Managing Director | 29-Aug-2007 | Current |
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Suman Jain | Whole-Time Director | 29-Aug-2007 | Current |
| Nisha Jain | Director | 27-Dec-2005 | Current |
| Manjudevi Laxmilal | Director | 12-Dec-2005 | Current |
Financial Performance of Richfield (India) Pharmaceuiticals.
Richfield (India) Pharmaceuiticals Private Limited, for the financial year ended 2023, experienced significant reduction in revenue, with a 12.75% decrease. The company also saw a substantial fall in profitability, with a 15.94% decrease in profit. The company's net worth Soared by an impressive increase of 33.61%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Richfield (India) Pharmaceuiticals?
In 2023, Richfield (India) Pharmaceuiticals had a promoter holding of 98.68% and a public holding of 1.32%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 15 Sep 2017 | ₹6.00 M | Open |
The United Western Bank Limited Creation Date: 01 Mar 2006 | ₹4.00 M | Open |
How Many Employees Work at Richfield (India) Pharmaceuiticals?
Richfield (India) Pharmaceuiticals has a workforce of 28 employees as of Mar 30, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Richfield (India) Pharmaceuiticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Richfield (India) Pharmaceuiticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
